Download Flash Player ►
Deltex Medical Group plc
www.deltexmedical.com/index.htmlProfil
Deltex Medical Group plc
Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.
Aktienkurs
Vorstellungen
Keine Unterlagen verfügbar.
Verbundene Recherche
Keine Unterlagen verfügbar.
Unternehmensstrategie und – daten:
Deltex Medical manufactures and sells medical monitors that are used by doctors and nurses to help patients recover more fully and more quickly from the effects of major surgery.
Deltex Medical is a British company, our products are researched, developed, and designed in the UK and are made at our factory in Chichester, West Sussex.
Multiple clinical trials have consistently demonstrated that using our products to ensure that patients receive the right amount of the right fluid at the right time during their surgery (‘Targeted Volume Management’ or ‘TVM’) reduces complications and means that patients can go home sooner than they otherwise would after their operation.
Deltex Medical’s CardioQ™™ monitor is unique in having been proven to be effective in improving patient outcomes and reducing length of hospital stay in repeated, rigorously controlled clinical trials.
To date, more than 300,000 patients have benefited from the use of the CardioQ™ in surgery and in intensive care and our aim is to establish the use of our products as a ‘standard of care’ for all patients undergoing major surgery or needing monitoring in intensive care.
Our products are manufactured to stringent quality standards, in a controlled environment, by trained technicians and are sold in over thirty countries around the world. The CardioQ™ and the probes used with it have an industry-leading track record for reliability and safety.
Aktuelle Tätigkeiten:
individualized Doppler Guided Fluid Management
All patients undergoing surgery are at risk from serious and potentially life-threatening complications caused by a reduction in circulating blood volume. This condition, known as hypovolaemia, results from the combined effects of pre-operative fasting, the anaesthetic agent and the blood lost during the surgical procedure. In many respects hypovolaemia can be thought of as akin to severe dehydration.
The complications that hypovolaemia causes arise because the reduced circulating blood volume is unable to carry sufficient oxygen to the major organs and tissues. All of these systems are at risk of failure as a consequence of the resultant oxygen deprivation.
The CardioQ™ monitors the flow of blood leaving the heart with every beat as it happens and consequently can detect any reduction in circulating blood volume early and in real-time. This allows the anaesthetist to intervene quickly and safely to correct the situation, using a combination of specialised fluids and drugs, before the hypovolaemia becomes serious and potentially life threatening. The technique of optimising a patientÕs haemodynamic status in this way, by giving the right amount of the right fluid at the right time, is known as individualized Doppler Guided Fluid Management.
Using the CardioQ™ to monitor and manage a patient’s circulating blood volume during surgery helps them to recover more fully and more quickly. Using the CardioQ™ means that fewer patients need to go to intensive care and those that do tend to stay there for shorter periods. Because patient journeys through the hospital are more predictable and because fewer patients unexpectedly need intensive care support, the CardioQ™ can play an important part in improving the efficiency and productivity of any healthcare system.
For more info on the individualized Doppler Guided Fluid Management CLICK HERE
Clinical Evidence
ODM-guided fluid management has been shown to reduce complications and length of hospital stay after surgery in multiple randomised controlled trials (RCTs) across different types of surgery. Every randomised controlled ODM trial has been positive.
These trials have been subject to a number of meta-analyses and systematic reviews:
* Two meta-analyses re ODM in abdominal surgery published1,2
* One meta-analysis re ODM across all applications published3
* A second meta-analysis re ODM in all settings presented4
* A health technology assessment (HTA) published by ECRI for the Agency for Healthcare Research & Quality (AHRQ)5
* A report by the Centers for Medicare and Medicaid Services based upon the ECRI HTA6
* A report by the UK Centre for Evidence-based Purchasing (CEP)7
* An HTA by the Aberdeen University Health Economic Research Unit commissioned by NIHR8
* A draft HTA re ODM in colorectal surgery by the Spanish government's Entralgo Agency9 and
* Assessment of ODM evidence as Level 1A for abdominal surgery and Level 1B for orthopedic surgery for UK consensus fluid guidelines10
All the above have concluded positively on the benefits of ODM. In effect the AHRQ/ECRI report concluded that, for a large group of surgical patients, no further clinical trials on ODM were necessary.
For further info on Clinical Evidence CLICK HERE
For info on Clinical Evidence CLICK HERE
For info on US Reimbursemen CLICK HERE
Management
Executive Directors of Deltex Medical
Ewan Phillips MA ACA
Position: Chief Executive
Ewan joined Deltex Medical in August 2001 and was appointed Chief Executive in 2009. He has a background in corporate finance and, prior to joining Deltex Medical, was Finance and Strategic Development Director of a technology Company supplying the UK public sector.
Email: [email protected]
Paul Mitchell BSc ACA
Position: Finance Director
Mr Mitchell joined Deltex Medical in August 2002 as Financial Controller, after qualifying as a Chartered Accountant with PricewaterhouseCoopers. In November 2004 he was appointed Company Secretary.
Non-Executive Directors of Deltex Medical
Nigel Keen MA FCA
Position: Chairman
Nigel has been involved with Deltex Medical since 1988, and has been Chairman since 1996. He is Chairman of the Remuneration Committee. Nigel served as Chief Executive from April 2002 to January 2003. He is also Chairman of Axis-Shield plc, The Laird Group plc and Oxford Instruments plc.
Hauptaktionäre
Number of shares in issue
The company's issued share capital comprises 129,883,609 ordinary shares of 1p each. All of the shares are fully paid; no shares are held as treasury shares. The percentage of shares not held in public hands is 11.54%.
Identity and percentage holdings of significant shareholders
As at 28 May 2010, the company had been notified of the following holdings of 3% or more of the voting rights of the company (as shareholder and as the direct or indirect holder of financial instruments) pursuant to transitional provision 7 of the DTR Sourcebook of the Disclosure and Transparency Rules:
• Gartmore Investment Limited – 10.78%
• Herald Investment Management Limited – 7.04%
• Charles Stanley & Co Limited – 5.21%
• Nigel Keen – 4.21%
Kontakt
Address
Deltex Medical Group plc, Terminus Road, Chichester, West Sussex, PO19 8TX.
Telephone
+44 1243 774837
Email
[email protected]
For further contact information CLICK HERE
Unternehmensinformationen
Solicitors
Laytons
Carmelite
50 Victoria Embankment
Blackfriars
London
EC4Y 0LS
Nominated Advisor and Broker
Arden Partners
Nicholas House
3 Laurence Pountney Hill
London EC4R 0EU
Principal Bankers
The Royal Bank of Scotland plc
62-63 Threadneedle Street
PO Box 412
London EC2R 8LA
Independent Auditors
PricewaterhouseCoopers LLP
Savannah House
3 Ocean Way
Ocean Village
Southampton
Hampshire SO14 3TJ
Registrars
Capita Registrars
Northern House
Woodsome Park
Fenay Bridge
Huddersfield HD8 0LA
Anleger, die in Deltex Medical Group plc interessiert sind, haben auch angesehen:
- ABM Resources (ASX: ABU)
- Algae.Tec (ASX: AEB)
- Allocate Software (AIM: ALL)
- Altus Strategies (AIM: Altus)
- Anglo Asian Mining (AIM: AAZ)
- Apella Resources Inc. (TSX-V: .APA)
- Arafura Resources (ASX: ARU)
- Argos Resources (AIM: ARG)
- ASX:BTV (ASX: BTV)
- Aura Energy Limited (ASX: AEE)
- Auzex Resources Limited (ASX: AZX)
- Avalon Rare Metals (TSX: AVL)
- Baobab Resources (AIM: BAO )
- Batavia Mining (ASX: BTV)
- Beowulf Mining plc (AIM: BEM)
- Cadillac Ventures, Inc (TSX-V: CDC)
- Camco (AIM: CAO )
- Central Petroleum (ASX: CTP)
- Cockatoo Coal (ASX: COK)
- Condor Resources (AIM: CNR)
- Continental Coal (ASX: CCC)
- Copper Fox Metals (TSX-V: CUU)
- Dragon Mining (ASX: DRA)
- Dragon Oil (LSE / ISE: DGO)
- e-Therapeutics plc (AIM: ETX)
- Eastmain Resources (TSX: ER)
- Eco Animal Health Group Plc (AIM: EAH)
- ECR Minerals (AIM: ECR)
- Elementos (ASX: ELT)
- Emmerson Resources (ASX: .ERM)
- Envirogold (ASX: EVG)
- Epistem (AIM: EHP)
- EurOmax Resources (TSX-V: EOX)
- Eurotin Inc. (TSX-V: ERT.P)
- Forte Energy (AIM / ASX: FTE)
- Frontier Rare Earths (TSX: FRO)
- Genesis Resources (ASX: GES)
- Gowest Gold (TSX-V: GWA)
- Great Western Minerals Group (TSX-V: GWG)
- Greenearth Energy Ltd. (ASX: .GER)
- Groote Resources (ASX: GOT)
- Gryphon Minerals (ASX: GRY)
- Gulf Resources (ASX: GLF)
- Halo Resources (TSX-V: HLO)
- Helius Energy Plc (AIM: HEGY)
- Icon Resources Limited (ASX: .III)
- IGas Energy Plc (AIM: IGAS)
- India Resources Ltd (ASX: IRL)
- Ironbark Zinc Limited (ASX: IBG)
- Ironclad Mining (ASX: IFE)
- IXR Resources (ASX: IXR)
- Jupiter Energy (ASX: JPR)
- Kalahari Resources Inc. (TSX-V: .KLA)
- Kentor Gold (ASX: KGL)
- Kiotech International (AIM: KIO)
- Knick Exploration (TSX-V: KNX)
- Legend Mining (ASX: LEG)
- Li3 Energy (OTCBB: LIEG)
- Metallica Minerals Ltd (ASX: .MLM)
- Millennium Minerals Limited (ASX: MOY)
- Millrock Resources (TSX-V: MRO)
- Mosquito Consolidated Gold Mines (TSX-V: MSQ)
- Mountain Lake Resources (TSX-V: MOA )
- Mutiny Gold (ASX: MYG)
- National Milk Records (PLUS: NMRP)
- Natural Resources USA Corporation (OTCBB: NTRC)
- NGM Resources (ASX: NGM)
- North River Resources (AIM: NRRP)
- NQ Exploration Inc (TSX-V: NQE)
- Ord River Resources Ltd (ASX: ORD)
- Orko Silver (TSX-V: OK)
- Ormonde Mining plc (AIM: ORM)
- Orosur Mining Inc. (AIM / TSX-V: OMI)
- Osceola Hydrocarbons (PLUS: OSCE)
- Ovoca Gold (AIM : OVG )
- Oxford Nutrascience (AIM: ONG)
- Peninsula Minerals (ASX: PEN)
- Petroceltic International (AIM: PCI)
- Planet Payment (AIM: PPT)
- Plato Gold Corp (TSX-V: PGC)
- Prosperity Minerals Holdings Limited (AIM: PMHL)
- Pulse Health Limited (ASX: .PHG)
- Pure Energy (TSX-V: PEV)
- Ram Resources (ASX : RMR)
- Range Resources (AIM / ASX: RRL)
- Renovo Group Plc (LSE: RNVO)
- Resource Generation (ASX: RES)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Rey Resources (ASX: .REY)
- Riverside Resources (TSX-V: RRI)
- Rodinia Minerals (TSX-V: .RM)
- SeaEnergy PLC (AIM: SEA)
- Selwyn Resources (TSX-V: .SWN)
- Senetek (OTCBB: SNKTY)
- Shaw River Resources (ASX: SRR)
- Shree Minerals (ASX: SHH)
- Siburan Resources (ASX: SBU)
- Silver Lake Resources (ASX: SLR)
- Simba Energy (TSX-V: SMB)
- Solo Oil (AIM: SOLO)
- Specialist Energy Group (AIM: SEGR)
- St. Elias Mines (TSX-V: SLI)
- Stellar Resources (ASX: SRZ)
- Sumatra Copper & Gold (ASX: SUM)
- Sun Resources (ASX: SUR)
- Syndicated Metals (ASX: SMD)
- Tantalus Rare Earths (XETRA: TAE)
- Tarsis Resources (TSX-V: .TCC)
- Thor Mining (AIM / ASX: THR)
- Thundelarra Exploration (ASX: THX)
- Urals Energy (AIM: UEN)
- US Nickel (ASX: USN)
- Wessex Exploration (PLUS: WX.P)
- Westgold Resources Limited (ASX: WGR)
- YTC Resources (ASX: YTC)
